Tamoxifen treatment fails to improve muscle dysfunction in a model of recessive RYR1-linked centronuclear myopathy
Charlotte Gineste, David Reiss, Jocelyn Laporte · 2025
Read Tamoxifen treatment fails to improve muscle dysfunction in a model of recessive RYR1-linked centronuclear myopathy by Charlotte Gineste, David Reiss, Jocelyn Laporte (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12805646.txt.
Description
Charlotte Gineste, David Reiss, and Jocelyn Laporte tested tamoxifen in myopathy mice in two thousand twenty-five. Centronuclear myopathies are rare inherited muscle disorders. No effective treatment exists for them. Tamoxifen helped mice with other genetic forms earlier. This model carries a recessive calcium-channel gene defect. Treated and untreated mice were compared over five weeks.
Muscle weakness persisted regardless of treatment. Fiber size stayed small in sick mice. Misplaced nuclei remained frequent too. Repeated contraction force actually fell with treatment. Related protein levels did not change. The drug offered no benefit in this form. It may even harm muscle function slightly.
Catalog record
| CREATOR | Charlotte Gineste, David Reiss, Jocelyn Laporte |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 48 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |